In the last years, Omnics EIS platform was demonstrated to be a valuable tool for point-of-care diagnostics, with the aim to allow fast screening of diseases with the target of a personalized medicine. Addressing the need of fast response and low cost analysis, a major aim in clinical and proteomic research is indeed to replace standard, time-spending and complex laboratory tools by new devices for analysis and high throughput evaluation of markers of interest, able to make immediate and sensitive diagnosis of pathological and threatening conditions. In this scenario, biorecognition events, as for example between antigens and antibodies or complementary DNA strands, can be easily detected by EIS measurements, since the interaction of immobilized capture probes with analytes/targets molecules results again in a change in capacitance and interfacial electron transfer resistance. In particular, our EIS biochips have been largely tested for the direct analysis of serum and biological fluids, being versatile and suitable for functionalization with different molecules and demonstrating minimal interference of unspecific adsorption of biological components. For example we demonstrated application for on-chip diagnostics of prostate cancer [ M. S. Chiriacò et al. Analyst 2013, Vol. 138, p. 5404-5410, issn., http://dx.doi.org/10.1039/C3AN00911D] or Pancreatic Ductal Adenocarcinoma [M. S. Chiriacò et al., Lab on a Chip 2013, Vol. 13, p. 730-734, issn. 1473-0197, http://dx.doi.org/10.1039/c2lc41127j] .
Recently, in collaboration with Dr. A. Paul and Prof. D.N. Srivastava (CSIR-CSMCRI, Gijubhai, India), a novel biosensor for picomolar detection of retinol binding protein 4 for early management of type II diabetes has been developed using homemade plastic chip electrodes (PCEs) [ A. Paul et al., Biosensors and Bioelectronics 2019, Vol. 128, p. 122-128, issn. 0956-5663, http://dx.doi.org/10.1016/j.bios.2018.12.032]
